Atezolizumab plus chemo before surgery for lung cancer
Treatments studied
Part of Cancer, Lungs & breathing clinical trials.
This trial studies whether adding atezolizumab (an immune medicine) to standard platinum-based chemotherapy before surgery can improve outcomes for operable stage II–IIIB non-small cell lung cancer. The goal is to shrink the tumor and increase the chance the cancer can be removed with better results.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 to 75 years old and willing to sign informed consent
- Your lung cancer must be confirmed non-small cell lung cancer and be operable (planned for curative surgery)
- You must not have had any prior treatment with chemotherapy or other cancer medicines
- Your tumor must be measurable on scans and you must have enough tumor tissue for lab testing
- Your health tests must show you can safely tolerate treatment and surgery (blood counts, liver/kidney tests, heart/EKG, and overall status)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether the immunotherapy drug atezolizumab, given before and after surgery, can help treat stage III non-small cell lung cancer that has not spread to other parts of the body. It is for people who have not had any previous cancer treatment for this disease.
This trial tests a combination of an immunotherapy drug (adebrelimab) plus chemotherapy and another drug (recaticimab) before and after surgery for people with stage II or III lung cancer that can be removed. The goal is to see if this approach helps shrink tumors and improves outcomes.
This trial studies whether giving different cancer medicines before (and sometimes after) surgery improves outcomes for people with early-stage, operable lung cancer that has certain tumor markers. It may help by trying to shrink or control the cancer early and lower the chance it comes back.
This trial tests whether adding new immunotherapy drugs (adebrelimab or retlirafusp alfa plus recaticimab) to standard chemotherapy before lung surgery can help people with resectable non-small cell lung cancer. The goal is to see if this combination improves outcomes for patients whose tumors can be surgically removed.
This trial tests adding the immunotherapy drug Adebrelimab to chemotherapy before surgery for people with a type of lung cancer that has certain gene changes. The goal is to see if this combination helps shrink the tumor and improve outcomes.
This trial tests a new combination of an immunotherapy drug (QL1706) plus chemotherapy given before and after surgery for people with certain stages of non-small cell lung cancer (NSCLC). The goal is to see if this approach helps shrink the tumor and improves outcomes.
Hear when a new Non Small Cell Lung Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.